AAV Titer and Purity Testing: The Complete QC Methods Guide

Accurate AAV titer determination and purity analysis of recombinant adeno-associated virus (rAAV) preparations are prerequisites for reproducible in vivo and in vitro experiments — and for regulatory-compliant batch release in translational programs. Whether you are preparing a single-serotype prep for a rodent injection study or qualifying a GMP lot for a clinical IND, the same core QC toolkit applies: genome titer, capsid titer, full-to-empty ratio, and purity assessment. This guide covers each method, explains what it actually measures, and helps you decide which assays belong in your batch release panel.

AAV Titer: Physical vs. Functional — What Each Number Means

Three distinct titer concepts are routinely reported for rAAV, and confusing them is one of the most common sources of lot-to-lot irreproducibility.

Genome titer (vg/mL) — physical titer of vector genomes. Quantifies the number of vector genome copies present in the preparation, regardless of whether those genomes are packaged inside intact capsids or whether those capsids are transduction-competent. Measured by qPCR or ddPCR (see below). This is the dosing unit for in vivo experiments and the most widely used AAV titer metric.

Capsid titer (total particles, vp/mL or cp/mL). Counts all capsid particles — full, empty, and partially filled — using an anti-capsid ELISA. Because an empty capsid contains no genome, capsid titer is always ≥ genome titer. The ratio of genome titer to capsid titer gives the full-to-empty fraction (see §4 below).

Functional (infectious) titer (TU/mL or IFU/mL). Measures only the transduction-competent particle fraction using cell-based assays: the transduction unit (TU) assay (count GFP- or reporter-positive cells after serial dilution), the TCID50 infectious center assay (with replication-permissive helper virus), or the replication center assay (RCA). Functional titer is typically 10- to 1,000-fold lower than genome titer — this ratio reflects the biological potency of the preparation and is influenced by serotype, production method, and purification. A physical:functional ratio in the 10–1,000× range is expected and published; it is not a preparation failure. For most research applications genome titer (vg/mL) is reported and used for dosing; functional titer serves as a secondary purity/potency indicator.

qPCR for AAV Genome Titer

Quantitative PCR (qPCR) is the most widely used method for genome titer determination in research-grade rAAV preparations. It amplifies vector DNA copies using primers and probe targeting the transgene cassette (ITR region, WPRE element, or promoter sequence) and quantifies against a linearized plasmid standard of known copy number.

Critical pre-treatment — DNase I digestion. Free plasmid DNA carried over from the HEK293 or Baculovirus production process contaminates the qPCR signal and systematically inflates the titer if not removed. DNase I treatment is not optional: it is the most important single step for accurate genome titer. Omitting or inadequately performing this step is the leading cause of artificially elevated titer measurements in published literature.

Protocol outline:

1. DNase I digestion: Add DNase I to 0.5–1 U/µL final concentration; incubate 37°C for 30 minutes. This degrades all unencapsidated (free) DNA.
2. DNase inactivation: Heat 75°C for 15 minutes (or add EDTA/EGTA to 10 mM to chelate Mg²⁺ and halt DNase activity).
3. Capsid lysis to release encapsidated genomes: Add Proteinase K to 200 µg/mL and incubate 65°C for 20 minutes; alternatively, add SDS to 0.5% and heat 70°C for 10 minutes. This step disrupts the capsid shell and releases the protected vector genome for PCR amplification.
4. qPCR: Run with a transgene-specific or WPRE-specific primer/probe set using TaqMan chemistry. SYBR Green is acceptable but carries higher non-specificity risk from primer-dimer artifacts at high dilution.
5. Absolute quantification: Use a six-point serial dilution of a linearized plasmid standard spanning 10² – 10⁸ copies/reaction.

Key variables and error sources: DNase treatment completeness (the dominant source of overestimation); primer/probe design — avoid ITR-spanning primers for certain serotype chimeras; standard curve linearity and accuracy (the plasmid standard must be linearized and its concentration verified by A₂₆₀). Typical genome titer range for research-grade AAV: 10¹² – 10¹³ vg/mL after iodixanol gradient or affinity chromatography purification.

ddPCR for AAV Genome Titer: Advantages and When to Use It

Digital droplet PCR (ddPCR) partitions the reaction into approximately 20,000 nanoliter-scale droplets before thermocycling. Each droplet undergoes an independent PCR reaction and is scored positive or negative by fluorescence amplitude. Absolute copy number is calculated by Poisson statistics from the ratio of positive-to-negative droplets — no standard curve is required.

Advantages over qPCR for AAV genome titer:

• No standard curve: eliminates the most common inter-laboratory variability source (differences in plasmid standard preparation)
• Better precision and reproducibility at low-to-moderate genome concentrations
• Preferred method for GMP lot release, regulatory submissions, and cross-site comparability studies (Lock et al., Human Gene Therapy, 2014)
• Less sensitive to PCR inhibitors at moderate dilution

Protocol notes specific to AAV: The same DNase I pre-treatment described above is required before ddPCR — the method does not inherently distinguish encapsidated from free DNA. Dilute the lysed sample 1:100 to 1:1,000 into the ddPCR reaction to land in the optimal droplet occupancy range (typically 800–6,000 positive droplets per 20,000). The same transgene-specific or WPRE primer/probe set used for qPCR works without modification.

ELISA-Based Capsid Titer and the Full/Empty Ratio

Anti-capsid ELISA kits quantify total AAV particles using serotype-specific antibodies directed against the outer surface of the capsid (VP1/VP2/VP3 epitopes). Unlike qPCR, the ELISA detects capsids irrespective of whether they contain a genome — so both full (genome-containing) and empty (genome-lacking) capsids are counted. The result is expressed as total viral particles per mL (vp/mL).

Calculating the full/empty ratio: With both genome titer (vg/mL by qPCR or ddPCR) and capsid titer (vp/mL by ELISA), the full capsid fraction is:

Full fraction (%) = (genome titer vg/mL ÷ capsid titer vp/mL) × 100

This works because a fully packaged AAV capsid contains exactly one vector genome. A preparation with a genome titer of 5 × 10¹² vg/mL and a capsid titer of 8 × 10¹² vp/mL therefore contains ~62.5% full capsids — the remainder are empty or partially packaged particles.

Acceptance thresholds: For most research-grade rAAV applications, a full capsid fraction ≥ 50–70% is considered acceptable, particularly when the preparation has been purified by iodixanol gradient. GMP products and clinical-grade lots typically target ≥ 90% full capsids, achieved by additional ion exchange chromatography or AUC-based fractionation to deplete empties.

ELISA-based capsid titer kits are available for the major clinical serotypes (AAV2, AAV5, AAV8, AAV9, and additional serotypes). If you are working with AAV vectors from BioHippo's catalog and need to establish an in-house QC panel, contact the technical team for guidance on which ELISA format is compatible with your serotype and production system.

Analytical Ultracentrifugation and AEX-HPLC for Full/Empty Ratio

When more precise quantification of the full/empty ratio is needed — or when fractionation of the two populations is required — biophysical separation methods are used.

Analytical ultracentrifugation (AUC) — sedimentation velocity. Full AAV2 capsids sediment at approximately 108 Svedberg (S) units; empty capsids sediment at approximately 66S; partially filled or aberrant particles sediment between these values. Sedimentation velocity experiments on an analytical ultracentrifuge (Beckman Optima AUC or equivalent) acquire absorbance or interference profiles as a function of time at 25,000–45,000 rpm. Data are fit using SEDFIT software (freely available from the NIH Biophysics Laboratory, Dr. Peter Schuck) to derive the c(s) distribution, which directly reports the fraction of full vs. empty capsids. AUC is the reference standard for full/empty quantification and is often required for regulatory submissions.

Anion exchange (AEX) HPLC. Full AAV capsids present different surface charge profiles than empty capsids — a consequence of genome-induced conformational differences in the outer capsid surface. This differential charge allows separation by anion exchange chromatography with a salt gradient, typically on a strong anion exchanger (e.g., Resource Q or MonoQ). Full and empty capsids elute at distinct salt concentrations and can be quantified by UV absorbance (A₂₈₀). AEX-HPLC is faster than AUC (a single run takes 30–60 minutes vs. 3–6 hours), amenable to automation, and is increasingly used in GMP manufacturing as a lot-release assay for full/empty ratio. Sensitivity and resolution vary by serotype — method development is typically required for non-AAV2 serotypes.

SDS-PAGE and Silver Stain for Purity Assessment

Gel-based purity assessment remains a fast, informative, and low-cost complement to the quantitative methods above. The three AAV capsid proteins — VP1 (~87 kDa), VP2 (~73 kDa), and VP3 (~62 kDa) — are resolved on a 4–12% Bis-Tris SDS-PAGE gel (MES or MOPS running buffer). Silver staining, which detects protein at sub-nanogram sensitivity, reveals contaminant bands that Coomassie blue would miss at typical rAAV loading amounts.

What to look for:

• VP1:VP2:VP3 band ratio. For most serotypes, the three bands appear in an approximately 1:1:10 molar ratio by Coomassie or silver stain — VP3 is the most abundant capsid subunit (the icosahedral T=1 capsid contains 60 total subunits, with VP3 making up the majority). Significant deviation from this pattern suggests atypical capsid assembly or contamination.
• Absence of major contaminant bands. For research-grade preparations, the lane should show three primary bands and faint minor bands only. Dominant contaminating protein bands indicate an inadequate purification. Baculovirus-based productions typically show more host cell protein contamination than triple-transfection HEK293 methods.
• Specific activity calculation. Total protein (measured by BCA assay) combined with genome titer gives specific activity in vg/µg total protein — a useful metric for comparing lots and production runs.

For in vivo studies, particularly CNS injections or systemic administration, purity-by-SDS-PAGE is typically required at lot release alongside genome titer. A clean three-band silver stain pattern is a strong qualitative indicator that the preparation meets research-grade purity standards.

AAV QC Reagents and Vectors at BioHippo

BioHippo distributes a broad catalog of ready-to-use recombinant AAV vectors across all major serotypes (AAV1 through AAV9 and beyond), each supplied with a Certificate of Analysis that includes qPCR-based genome titer, SDS-PAGE purity assessment, and sterility data. Vectors are typically supplied at 1 × 10¹³ vg/mL in 10 or 30 µL trial and standard pack sizes.

For QC workflows, the BioHippo catalog also includes anti-AAV capsid antibodies validated for ELISA applications — useful for building in-house capsid titer assays or confirming serotype identity by immunoblot. Browse the Adeno-Associated Viruses (AAVs) collection for the full range of vectors, or use the site search at ebiohippo.com to filter by serotype or application.

For additional background on AAV biology, serotype selection, and tropism, see the BioHippo overview article: Adeno-Associated Virus (AAV) — An Introduction.

Frequently Asked Questions

How do you measure AAV titer?

AAV titer is most commonly measured by quantitative PCR (qPCR) targeting the vector genome sequence (ITR region, WPRE, or transgene). The preparation is first treated with DNase I to remove unencapsidated plasmid DNA, then the capsids are lysed with Proteinase K or SDS to release the protected genomes, and the extracted DNA is quantified by qPCR against a linearized plasmid standard. The result is expressed in vector genomes per milliliter (vg/mL). Digital droplet PCR (ddPCR) provides the same measurement without a standard curve and is increasingly preferred for GMP applications. ELISA-based assays using anti-capsid antibodies measure total particle count (vp/mL), which includes both full and empty capsids.

What is the difference between physical and functional AAV titer?

Physical titer (genome titer, vg/mL) counts all vector genome copies in the preparation — it does not distinguish transduction-competent particles from non-infectious ones. Functional titer (transduction units, TU/mL) counts only the particles capable of delivering their genome to a cell and driving transgene expression, as measured in a cell-based assay. Physical titer is always higher than functional titer; the ratio typically falls between 10:1 and 1,000:1 depending on serotype, production method, and purification. Functional titer is not routinely reported in most research settings but is important for potency assessment in translational or therapeutic applications.

What is the full to empty ratio for AAV, and how is it measured?

The full-to-empty ratio is the fraction of capsid particles in a preparation that contain a packaged vector genome. It is calculated by dividing the genome titer (vg/mL by qPCR or ddPCR) by the total capsid titer (vp/mL by ELISA) and expressing the result as a percentage. A ratio of 70% or higher is generally considered acceptable for research-grade AAV. GMP lots targeting clinical applications typically require ≥ 90% full capsids. For higher-resolution measurement or preparative separation, analytical ultracentrifugation (AUC) or anion exchange HPLC (AEX-HPLC) resolves full (~108S) and empty (~66S) capsid populations directly.

Should I use qPCR or ddPCR for AAV genome titration?

For routine in-house genome titer measurement in a research setting, qPCR with a well-validated plasmid standard is sufficient and cost-effective. ddPCR is preferred when: (1) you need absolute quantification without standard curve uncertainty, (2) you are comparing titers across laboratories or production lots, (3) the preparation is at low concentration and precision is critical, or (4) you are generating data for a regulatory submission or GMP lot release where cross-site reproducibility is required. Both methods require the same DNase I pre-treatment; the choice comes down to instrumentation access and the precision requirements of your program.

What purity is required for in vivo AAV experiments?

For most rodent in vivo studies, research-grade AAV purified by iodixanol density gradient or affinity chromatography and showing three clean VP1/VP2/VP3 bands by silver-stained SDS-PAGE is sufficient. A genome titer of 10¹² – 10¹³ vg/mL and a full capsid fraction ≥ 50–70% is typical for this application. For non-human primate studies or any work that will inform clinical translation, purity requirements are significantly higher: full capsid fraction ≥ 90% (confirmed by AUC or AEX-HPLC), host cell protein quantification, residual DNA by qPCR, and endotoxin testing are all typically required. Always consult your institutional IACUC guidelines and, for translational programs, the relevant regulatory guidance (FDA Guidance for Industry on Gene Therapy Products) for the complete lot release specification.